{"filings":[{"id":92890,"accession_number":"0001439222-26-000071","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q1 mitapivat revenue $20.7M; 242 AQVESME scrips; sCD sNDA plan in Q2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide mitapivat net revenue $20.7M in Q1 2026, up from $8.7M in Q1 2025.","242 AQVESME prescriptions for thalassemia by U.S. REMS-certified physicians as of March 31, 2026.","Plans to submit mitapivat sNDA for sickle cell disease under accelerated approval pathway in Q2 2026.","Net loss $99.1M in Q1 2026 vs $89.3M in Q1 2025.","Cash and equivalents $1.0B as of March 31, 2026, down from $1.2B at Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":20746000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104086,"accession_number":"0001439222-26-000023","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q4 net loss $108M; AQVESME approved for thalassemia, U.S. launch started","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PYRUKYND worldwide net revenue $20M in Q4 ($16M U.S., $4M ex-U.S.), up 49% YoY in U.S.","Full-year 2025 PYRUKYND revenue $54M; net loss $108M in Q4 vs $96.5M in Q4 2024.","FDA approved AQVESME (mitapivat) for thalassemia in Dec 2025; U.S. launch began late Jan 2026.","Pre-sNDA meeting with FDA for mitapivat in sickle cell disease expected Q1 2026.","Phase 2 tebapivat trial in sickle cell disease fully enrolled; topline data in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":54028000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104085,"accession_number":"0001439222-26-000018","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Agios outlines 2026 milestones: AQVESME launch in thalassemia, potential sNDA for sickle cell disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AQVESME (mitapivat) U.S. approval in thalassemia Dec 2025; commercial launch underway, product available late Jan 2026.","Pre-sNDA meeting with FDA for mitapivat in sickle cell disease expected Q1 2026; U.S. submission to follow.","Pipeline: tebapivat Phase 2 sickle cell topline H2 2026; Phase 2b LR-MDS topline H1 2026.","AG-236 (siRNA for PV) Phase 1 healthy volunteer topline H1 2026; AG-181 Phase 1b PKU trial init H1 2026.","Target >$1B peak global sales from existing thalassemia and PK deficiency commercial presence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120366,"accession_number":"0001439222-25-000114","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q3 PYRUKYND rev $12.9M (+44% YoY); net loss $103.4M; thalassemia PDUFA Dec 7","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 PYRUKYND net revenue $12.9M (+44% YoY vs $9.0M); 149 U.S. patients on therapy.","Net loss $103.4M in Q3 2025 vs net income $947.9M in Q3 2024 (prior-year milestone payments).","Cash $1.3B; PDUFA goal date Dec 7, 2025 for PYRUKYND sNDA in thalassemia.","CHMP positive opinion for PYRUKYND in thalassemia; EC decision expected early 2026.","RISE UP Phase 3 sickle cell disease topline results by year-end; tebapivat Phase 2b topline early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":34061000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136942,"accession_number":"0001439222-25-000090","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Agios responds to analyst report on PYRUKYND safety data; Saudi Arabia approves PYRUKYND for thalassemia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Analyst report on Aug 4, 2025 references four FAERS cases; Agios says benefit-risk profile unchanged.","Three cases reported to Agios: two for PK deficiency patients on commercial PYRUKYND, one expanded access for sickle cell.","Fourth case reported directly to FDA; Agios evaluating via pharmacovigilance processes.","Saudi FDA approved PYRUKYND for adult patients with alpha- or beta-thalassemia (both non-transfusion and transfusion dependent)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136941,"accession_number":"0001439222-25-000087","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q2 2025 net loss $112M; PYRUKYND revenue $12.5M; PDUFA Sept 7 for thalassemia","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $112.0M vs $96.1M YoY; PYRUKYND net revenue $12.5M, up from $8.6M in Q2 2024.","Cash and marketable securities $1.3B; expects to fund potential thalassemia and SCD launches.","FDA PDUFA goal date for PYRUKYND sNDA in thalassemia is Sept 7, 2025; launch prep underway.","RISE UP Phase 3 topline for mitapivat in sickle cell disease on track by year-end 2025.","Dosed first patient in tebapivat Phase 2 for SCD; IND clearance for AG-236 siRNA for PV."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":21181000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136940,"accession_number":"0001439222-25-000076","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Agios Pharmaceuticals elects Jay Backstrom, M.D., MPH to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Backstrom appointed as Class III director, term until 2028 Annual Meeting.","Appointed to Science and Technology Committee of the Board effective July 8, 2025.","Initial compensation includes stock option with $472,500 Black-Scholes value and RSUs valued at $157,500.","Annual cash compensation: $50,000 for board service plus $7,500 for committee service, quarterly pro-rata."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154199,"accession_number":"0001193125-25-142745","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Agios shareholders elect two directors, approve 2.5M share plan increase and say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors Jacqualyn A. Fouse and David Scadden elected with 45.96M and 46.20M votes for, respectively.","Non-binding say-on-pay approved: 46.84M for, 3.02M against, 16,430 abstain.","2023 Stock Incentive Plan amendment approved: 31.68M for, 18.20M against (36.5% opposition), adding 2.5M authorized shares.","Ratification of PricewaterhouseCoopers as auditor: 51.20M for, 136,734 against, 22,781 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154198,"accession_number":"0001439222-25-000034","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q1 PYRUKYND revenue $8.7M; PDUFA Sept 7 for thalassemia; net loss $89.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PYRUKYND net revenue $8.7M in Q1 2025 vs $8.2M in Q1 2024; 136 patients on therapy.","FDA accepted sNDA for thalassemia with PDUFA goal date September 7, 2025; no advisory committee planned.","Phase 3 RISE UP in sickle cell disease topline results expected late 2025; potential US launch in 2026.","Net loss $89.3M in Q1 2025 vs $81.5M in Q1 2024; cash and securities $1.4B as of March 31, 2025.","Krishnan Viswanadhan appointed Chief Corporate Development and Strategy Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":8726000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172793,"accession_number":"0001439222-25-000007","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q4: PYRUKYND revenue $10.7M, mitapivat PDUFA Sept 7, 2025; cash $1.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PYRUKYND net revenue $10.7M in Q4 (+20% QoQ), full year $36.5M vs $26.8M in 2023.","Filed for mitapivat approval in thalassemia in US, EU, KSA, UAE; PDUFA goal date Sept 7, 2025.","Phase 3 RISE UP for sickle cell disease fully enrolled (>200 patients); topline results late 2025, potential launch 2026.","Cash, cash equivalents and marketable securities $1.5B as of Dec 31, 2024; net loss Q4 $96.5M, full year net income $673.7M.","Board member David Schenkein to step down effective Feb 28, 2025; remains as strategic advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":11.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":36498000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172792,"accession_number":"0001193125-25-025524","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Agios board member David Schenkein resigns effective Feb 28, 2025; stays as strategic advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Schenkein notified company of resignation from board on Feb 10, 2025, effective Feb 28, 2025.","He will also cease serving on the Science and Technology Committee of the board.","He will continue as a strategic advisor to leadership, focusing on advancing clinical development programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172791,"accession_number":"0001193125-25-004943","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Agios announces 2025 milestones: PYRUKYND PDUFA Sept 7; RISE UP topline in late 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA accepted sNDA for PYRUKYND in thalassemia; PDUFA goal date September 7, 2025.","Phase 3 RISE UP topline results expected late 2025; potential U.S. commercial launch in 2026.","Received $1.1B in milestone payments: $905M from Royalty Pharma, $200M from Servier post vorasidenib approval.","Phase 3 ACTIVATE-Kids topline in early 2025; Phase 2b tebapivat enrollment completion late 2025.","IND filing planned for AG-236 siRNA in polycythemia vera mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172790,"accession_number":"0001193125-25-001809","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"FDA adds liver injury warning to PYRUKYND label for PK deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved update to PYRUKYND USPI: liver injury observed in patients with another condition at higher doses.","New Warnings: obtain liver tests before initiation, monthly for first 6 months, interrupt if ALT >5x ULN.","All patients with liver injury discontinued PYRUKYND and improved upon discontinuation.","Adverse Reactions section updated to reflect hepatocellular injury in another condition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189808,"accession_number":"0001439222-24-000136","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios reports Q3 net income of $947.9M on $1.1B milestone payments; PYRUKYND rev $9.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $947.9M vs loss $91.3M YoY; driven by $1.1B payments from Royalty Pharma & Servier.","PYRUKYND net revenue $9.0M (+4% QoQ); 127 patients on therapy, 211 enrollment forms.","Completed enrollment of Phase 3 RISE UP for mitapivat in SCD; topline data expected late 2025.","Initiated Phase 2b of tebapivat in LR-MDS; FDA orphan drug designation for MDS received.","Cash, equivalents and securities $1.7B at Sept 30, 2024, up from $806.4M at Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":13.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":25768000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206313,"accession_number":"0001439222-24-000117","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q2 2024 net loss $96.1M; PYRUKYND rev $8.6M; plans thalassemia sNDA by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PYRUKYND net revenue $8.6M in Q2 2024, up 5% sequentially; 128 patients on therapy.","Net loss $96.1M vs $83.8M YoY; cash, equivalents, marketable securities $645.3M at June 30.","Phase 3 ENERGIZE-T met primary endpoint in transfusion-dependent thalassemia; sNDA filing planned by end of 2024.","Announced $905M purchase agreement with Royalty Pharma for vorasidenib royalty; total $1.1B payable upon FDA approval.","Announced ACTIVATE-KidsT topline data in pediatric PK deficiency; ACTIVATE-Kids enrollment complete, data in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":16804000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223415,"accession_number":"0001193125-24-164555","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Agios shareholders elect four Class II directors, approve say-on-pay, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Kaye Foster (45.8M for, 5.3M withheld), Maykin Ho (46.7M for, 4.4M withheld), Jeffrey Capello (47.8M for, 3.3M withheld), Catherine Owen (45.6M for, 5.5M withheld) as Class II directors.","Advisory vote on named executive officer compensation approved: 48.0M for, 3.1M against, 13,404 abstaining.","Ratified PricewaterhouseCoopers LLP as independent auditor: 52.3M for, 70,843 against, 2,396 abstaining."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223414,"accession_number":"0001193125-24-147583","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Agios sells vorasidenib royalty rights to Royalty Pharma for $905M upfront upon FDA approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Royalty Pharma pays $905M to Agios upon FDA approval of vorasidenib (PDUFA date Aug 20, 2024).","Agios retains $200M milestone from Servier upon approval; total potential cash inflow of ~$1.1B.","Royalty Pharma receives 15% royalty on first $1B annual US sales; Agios retains 3% on sales above $1B.","Proceeds intended to fund PYRUKYND launches in thalassemia/sickle cell and expand pipeline.","Transaction closing requires FDA approval by Oct 31, 2024 and other customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223413,"accession_number":"0001439222-24-000067","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q1 2024 PYRUKYND revenue $8.2M; net loss $81.5M; mitapivat ENERGIZE-T readout Q2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PYRUKYND net revenue $8.2M in Q1 2024, up 15% sequentially; 120 patients on therapy.","Net loss $81.5M in Q1 2024 vs $81.0M in Q1 2023; cash $714.3M as of March 31, 2024.","Positive Phase 3 ENERGIZE results for mitapivat in non-transfusion-dependent thalassemia announced in January.","ENERGIZE-T topline data expected Q2 2024; FDA filing for mitapivat in thalassemia planned year-end.","Servier's vorasidenib NDA accepted with PDUFA Aug 20, 2024; Agios eligible for $200M milestone and 15% royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":8189000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}